Seeing further.


We’re advancing our RNA-based treatments so patients with cancer can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Provides Corporate Update

EXTON, Pa. , April 10, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:… Read more 

Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting

– Tilsotolimod activated IFN-α and MHC class II genes in the tumor microenvironment across… Read more 

Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

– ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 – – ILLUMINATE-204 Enrollment… Read more 

Learn More


Idera Pharmaceuticals, Inc. Events

Idera Pharmaceuticals, Inc. Events… Read more 

Learn More